Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BDX 
Becton Dickinson and Company (BDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: BDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $208
1 Year Target Price $208
| 4 | Strong Buy |
| 2 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.12% | Avg. Invested days 44 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 53.55B USD | Price to earnings Ratio 34.16 | 1Y Target Price 208 |
Price to earnings Ratio 34.16 | 1Y Target Price 208 | ||
Volume (30-day avg) 17 | Beta 0.3 | 52 Weeks Range 161.47 - 248.00 | Updated Date 09/14/2025 |
52 Weeks Range 161.47 - 248.00 | Updated Date 09/14/2025 | ||
Dividends yield (FY) 2.14% | Basic EPS (TTM) 5.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.41% | Operating Margin (TTM) 17.81% |
Management Effectiveness
Return on Assets (TTM) 3.96% | Return on Equity (TTM) 6.18% |
Valuation
Trailing PE 34.16 | Forward PE 12.15 | Enterprise Value 72137476307 | Price to Sales(TTM) 2.5 |
Enterprise Value 72137476307 | Price to Sales(TTM) 2.5 | ||
Enterprise Value to Revenue 3.37 | Enterprise Value to EBITDA 14.67 | Shares Outstanding 286627008 | Shares Floating 285994022 |
Shares Outstanding 286627008 | Shares Floating 285994022 | ||
Percent Insiders 0.57 | Percent Institutions 92.25 |
Upturn AI SWOT
Becton Dickinson and Company
Company Overview
History and Background
Becton Dickinson and Company (BD) was founded in 1897. Initially a medical device importer, it evolved into a global leader in medical technology, diagnostics, and biosciences. Key milestones include early syringe manufacturing, expansion into diagnostics, and strategic acquisitions to broaden its portfolio.
Core Business Areas
- BD Medical: Manufactures medical devices and products used in medication delivery, surgery, and infection prevention.
- BD Life Sciences: Provides products for diagnostics, including specimen management systems, microbiology solutions, and molecular diagnostics.
- BD Interventional: Offers devices for peripheral intervention, surgery, and urology/critical care.
Leadership and Structure
BD's leadership team includes CEO Thomas Polen. The company is structured into business segments, with corporate functions supporting these divisions.
Top Products and Market Share
Key Offerings
- BD Vacutainer Tubes: Blood collection tubes used globally in healthcare settings. BD is a leading supplier in this market, competing with Greiner Bio-One and Sekisui Diagnostics. Estimated market share around 40%.
- BD Alaris Pump: Infusion pump systems for medication delivery. Competitors include Baxter, ICU Medical, and Smiths Medical. Estimated market share around 25%.
- BD PosiFlush: Pre-filled saline syringes for flushing IV lines. Addresses infection prevention and improves efficiency. Competitors include Medtronic and Cardinal Health.
Market Dynamics
Industry Overview
The medical technology and diagnostics industry is driven by aging populations, increasing healthcare spending, and technological advancements. Growing demand for minimally invasive procedures and point-of-care diagnostics are also significant trends.
Positioning
BD holds a strong position due to its broad product portfolio, global presence, and focus on innovation. Its competitive advantages include brand recognition, extensive distribution network, and strong relationships with healthcare providers.
Total Addressable Market (TAM)
The global medical technology market is estimated at over $500 billion. BD is well-positioned to capture a significant share of this market through its diverse offerings and strategic focus areas.
Upturn SWOT Analysis
Strengths
- Global Brand Recognition
- Extensive Product Portfolio
- Strong Distribution Network
- Focus on Innovation
- Established Relationships with Healthcare Providers
Weaknesses
- Exposure to Currency Fluctuations
- Dependence on Regulatory Approvals
- Potential for Product Liability Claims
- Integration Challenges from Acquisitions
Opportunities
- Expanding into Emerging Markets
- Developing New Diagnostic Technologies
- Acquiring Complementary Businesses
- Leveraging Digital Health Solutions
- Increased Focus on Preventative Care
Threats
- Intense Competition
- Pricing Pressures from Healthcare Payers
- Changes in Healthcare Regulations
- Economic Downturns
- Supply Chain Disruptions
Competitors and Market Share
Key Competitors
- TMO
- DHR
- MMM
- SYK
Competitive Landscape
BD competes on product breadth, innovation, and global reach. Strengths include its established brand and distribution network. Weaknesses can include integration risks from acquisitions and pricing pressures.
Major Acquisitions
CareFusion
- Year: 2015
- Acquisition Price (USD millions): 12200
- Strategic Rationale: Expanded BD's medication management and patient safety solutions.
Bard
- Year: 2017
- Acquisition Price (USD millions): 24000
- Strategic Rationale: Strengthened BD's position in the high-growth vascular access and urology markets.
Growth Trajectory and Initiatives
Historical Growth: BD has experienced growth through organic expansion and strategic acquisitions.
Future Projections: Analysts expect continued growth in revenue and earnings, driven by demand for medical technology and diagnostics.
Recent Initiatives: Recent initiatives include investments in R&D, expansion into emerging markets, and acquisitions to strengthen its portfolio.
Summary
Becton Dickinson is a major player in the medical device and diagnostics industry. Its diversified product portfolio, global presence, and strategic acquisitions drive growth. The company faces challenges, including intense competition and regulatory hurdles, but its focus on innovation and market expansion positions it for future success. BD must effectively integrate acquisitions and navigate pricing pressures to maintain its competitive edge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Website
- Market Research Reports (e.g., EvaluateMedTech, Statista)
- Analyst Reports (e.g., from major investment banks)
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on available data. Financial data and projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Becton Dickinson and Company
Exchange NYSE | Headquaters Franklin Lakes, NJ, United States | ||
IPO Launch date 1987-01-01 | President, CEO & Chairman Mr. Thomas E. Polen Jr. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 70000 | Website https://www.bd.com |
Full time employees 70000 | Website https://www.bd.com | ||
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.